TCM Biotech International (ROCO:4169) Debt-to-Equity : 0.12 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is TCM Biotech International Debt-to-Equity?

TCM Biotech International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$59.0 Mil. TCM Biotech International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$64.5 Mil. TCM Biotech International's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$1,055.0 Mil. TCM Biotech International's debt to equity for the quarter that ended in Dec. 2023 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TCM Biotech International's Debt-to-Equity or its related term are showing as below:

ROCO:4169' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.27 Max: 0.32
Current: 0.12

During the past 13 years, the highest Debt-to-Equity Ratio of TCM Biotech International was 0.32. The lowest was 0.02. And the median was 0.27.

ROCO:4169's Debt-to-Equity is ranked better than
54.78% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:4169: 0.12

TCM Biotech International Debt-to-Equity Historical Data

The historical data trend for TCM Biotech International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCM Biotech International Debt-to-Equity Chart

TCM Biotech International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.30

0.27

0.32

0.12

TCM Biotech International Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.32	0.31	0.32	0.30	0.12

Competitive Comparison of TCM Biotech International's Debt-to-Equity

For the Biotechnology subindustry, TCM Biotech International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TCM Biotech International's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCM Biotech International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TCM Biotech International's Debt-to-Equity falls into.

TCM Biotech International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TCM Biotech International's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(58.972	+	64.502)	/	1055.042
	=	0.12

TCM Biotech International's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(58.972	+	64.502)	/	1055.042
	=	0.12

TCM Biotech International (ROCO:4169) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TCM Biotech International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TCM Biotech International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TCM Biotech International (ROCO:4169) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCM Biotech International Corp (ROCO:4169) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 97, Sec. 1, Xintai 5th Road, Xizhi District, Neihu District, Taipei, TWN, 221

Website

http://www.tcmbio.com

TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.

TCM Biotech International (ROCO:4169) Headlines

No Headlines